⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for akt

Every month we try and update this database with for akt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaNCT01466868
Diffuse Large B...
MK2206
18 Years - 90 YearsCentre Leon Berard
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaNCT01473095
Solid Tumor
Malignant Lymph...
Tumor
ARQ 092
18 Years - ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaNCT01473095
Solid Tumor
Malignant Lymph...
Tumor
ARQ 092
18 Years - ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693NCT00493818
Cancer
GSK690693
18 Years - GlaxoSmithKline
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung CancerNCT00342836
AKT
Akt levels
40 Years - 74 YearsNational Institutes of Health Clinical Center (CC)
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid TumorsNCT01562275
Neoplasms
Ipatasertib
Cobimetinib
18 Years - Genentech, Inc.
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid TumorsNCT01562275
Neoplasms
Ipatasertib
Cobimetinib
18 Years - Genentech, Inc.
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular AnomaliesNCT03317366
Proteus Syndrom...
PIK3CA-Related ...
Growth Disorder...
ARQ 092
2 Years - ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung CancerNCT00342836
AKT
Akt levels
40 Years - 74 YearsNational Institutes of Health Clinical Center (CC)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: